107 related articles for article (PubMed ID: 21332707)
1. Aspergillus fumigatus osteomyelitis in a patient receiving alemtuzumab for B-cell chronic lymphocytic leukaemia.
Karia S; Jeyapalan K; Kennedy B
Br J Haematol; 2011 Apr; 153(2):147. PubMed ID: 21332707
[No Abstract] [Full Text] [Related]
2. Prostatic and renal aspergillosis due to Aspergillus fumigatus in a patient receiving alemtuzumab for chronic lymphocytic leukaemia.
Roux C; Thyss A; Gari-Toussaint M
J Mycol Med; 2013 Dec; 23(4):270-3. PubMed ID: 24210582
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab and myelodysplasia: a story of love and hate (possible alemtuzumab-induced myelodysplastic changes).
Braester A; Akria L; Suriu C; Sonkin V
Acta Haematol; 2013; 129(3):185-6. PubMed ID: 23257842
[No Abstract] [Full Text] [Related]
4. Disseminated cryptococcosis, invasive aspergillosis, and mucormycosis in a patient treated with alemtuzumab for chronic lymphocytic leukaemia.
Henn A; Mellon G; Benoît H; Roos-Weil D; Jauréguiberry S; Mordant P; Fekkar A; Caumes E
Scand J Infect Dis; 2014 Mar; 46(3):231-4. PubMed ID: 24450842
[TBL] [Abstract][Full Text] [Related]
5. Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia.
Reda G; Maura F; Gritti G; Gregorini A; Binda F; Guidotti F; Piciocchi A; Visco C; Rodeghiero F; Cortelezzi A
Am J Hematol; 2012 Sep; 87(9):936-7. PubMed ID: 22718434
[TBL] [Abstract][Full Text] [Related]
6. Unexplained severe Coombs-negative hemolytic anemia during treatment of refractory chronic lymphocytic leukemia with alemtuzumab.
Niscola P; Ragusa D; Scaramucci L; Giovannini M; Piccioni D; Tendas A; Perrotti A; de Fabritiis P; Del Poeta G
Ann Hematol; 2014 May; 93(5):863-5. PubMed ID: 23949377
[No Abstract] [Full Text] [Related]
7. Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia.
Pitini V; Cascio A; Arrigo C; Altavilla G
Br J Haematol; 2012 Jan; 156(1):1. PubMed ID: 21790529
[No Abstract] [Full Text] [Related]
8. An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients.
Cortelezzi A; Gritti G; Laurenti L; Cuneo A; Ciolli S; Di Renzo N; Musto P; Mauro FR; Cascavilla N; Falchi L; Zallio F; Callea V; Maura F; Martinelli S; Piciocchi A; Reda G; Foà R;
Br J Haematol; 2012 Feb; 156(4):481-9. PubMed ID: 22150204
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression.
Sylvan SE; Rossmann E; Mozaffari F; Porwit A; Norin S; Karlsson C; Hansson L; Lundin J; Österborg A
Br J Haematol; 2012 Dec; 159(5):608-12. PubMed ID: 23043283
[No Abstract] [Full Text] [Related]
10. Pact with the devil: alemtuzumab therapy, immune suppression and infectious complications in chronic lymphocytic leukemia.
Antohe I; Dascalescu A; Burcoveanu C; Ghiorghiu D; Dascalu A; Danaila C
Rev Med Chir Soc Med Nat Iasi; 2014; 118(1):92-5. PubMed ID: 24741782
[TBL] [Abstract][Full Text] [Related]
11. Obinutuzumab (Gazyva) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2014 Nov; 56(1455):e114-5. PubMed ID: 25538980
[No Abstract] [Full Text] [Related]
12. Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia.
Thachil J; Salim R
Leuk Res; 2007 Jul; 31(7):1025-6. PubMed ID: 17005249
[No Abstract] [Full Text] [Related]
13. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia.
Anoop P; Wotherspoon A; Matutes E
Br J Haematol; 2010 Feb; 148(3):484-6. PubMed ID: 19874308
[No Abstract] [Full Text] [Related]
14. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration.
Abad S; Gyan E; Moachon L; Bouscary D; Sicard D; Dreyfus F; Blanche P
Clin Infect Dis; 2003 Jul; 37(2):e27-8. PubMed ID: 12856232
[TBL] [Abstract][Full Text] [Related]
15. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
Demko S; Summers J; Keegan P; Pazdur R
Oncologist; 2008 Feb; 13(2):167-74. PubMed ID: 18305062
[TBL] [Abstract][Full Text] [Related]
16. Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab.
Laurenti L; Tarnani M; Innocenti I; Savino G; Battendieri R; Larocca LM; Chiusolo P; Sorà F; Sica S; Efremov D; Leone G
J Clin Oncol; 2008 Nov; 26(32):5299-301. PubMed ID: 18854557
[No Abstract] [Full Text] [Related]
17. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
O'Brien SM; Keating MJ; Mocarski ES
Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
[TBL] [Abstract][Full Text] [Related]
18. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
Laros-van Gorkom BA; Huisman CA; Wijermans PW; Schipperus MR
Neth J Med; 2007 Oct; 65(9):333-8. PubMed ID: 17954952
[TBL] [Abstract][Full Text] [Related]
19. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).
Wendtner CM; Ritgen M; Schweighofer CD; Fingerle-Rowson G; Campe H; Jäger G; Eichhorst B; Busch R; Diem H; Engert A; Stilgenbauer S; Döhner H; Kneba M; Emmerich B; Hallek M;
Leukemia; 2004 Jun; 18(6):1093-101. PubMed ID: 15071604
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of alemtuzumab in cutaneous chronic lymphocytic leukaemia involving facial skin.
Grey M
Br J Haematol; 2008 Jul; 142(1):1. PubMed ID: 18477054
[No Abstract] [Full Text] [Related]
[Next] [New Search]
